Litigation Details for AbbVie Inc. v. Boehringer Ingelheim International GMBH (D. Del. 2017)

AbbVie Inc. v. Boehringer Ingelheim International GMBH (D. Del. 2017)

Docket		Date Filed	2017-08-02
Court	District Court, D. Delaware	Date Terminated	2019-05-15
Cause	35:0145	Assigned To	Mitchell S. Goldberg
Jury Demand	None	Referred To	Richard A. Lloret
Parties	BOEHRINGER INGELHEIM FREMONT, INC.
Patents	8,231,876; 8,663,945; 8,715,664; 8,883,156; 8,889,136; 8,895,009; 8,906,372; 8,906,646; 8,911,964; 8,916,153; 8,926,975; 8,999,337; 9,062,106; 9,085,618; 9,090,688; 9,090,867; 9,096,666; 9,102,723; 9,150,645; 9,234,032; 9,266,949; 9,273,132; 9,284,370; 9,284,371; 9,290,568; 9,315,574; 9,328,165; 9,334,319; 9,346,879; 9,359,434; 9,499,614; 9,505,834; 9,522,953; 9,624,295; 9,669,093; 9,683,033
Attorneys	Mindy L. Ehrenfried
Firms	Ross Aronstam & Moritz LLP
Link to Docket	External link to docket

Details for AbbVie Inc. v. Boehringer Ingelheim International GMBH (D. Del. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-08-02				External link to document

AbbVie Inc. v. Boehringer Ingelheim: Litigation Summary and Patent Analysis, 1:17-cv-01065

Last updated: August 4, 2026

AbbVie Inc. v. Boehringer Ingelheim International GmbH, No. 1:17-cv-01065, was a U.S. patent dispute concerning Boehringer Ingelheim's adalimumab biosimilar, later marketed as Cyltezo, or adalimumab-adbm. AbbVie asserted Humira-related patents after Boehringer pursued FDA approval under the Biologics Price Competition and Innovation Act. The parties settled in 2018. The settlement permitted Boehringer to launch Cyltezo in the United States on July 1, 2023, subject to confidential terms. The case ended without a merits ruling invalidating or enforcing the asserted patents.

What was AbbVie v. Boehringer Ingelheim about?

The case concerned whether Boehringer's adalimumab biosimilar infringed patents covering Humira, adalimumab formulations, and methods of treatment.

Item	Detail
Court	U.S. District Court for the District of Delaware
Case number	1:17-cv-01065
Plaintiff	AbbVie Inc.
Defendant	Boehringer Ingelheim International GmbH and related entities
Reference product	Humira, adalimumab
Biosimilar	BI 695501, later Cyltezo, adalimumab-adbm
FDA pathway	Section 351(k) biosimilar application
Filing year	2017
Resolution	Settlement in 2018
U.S. launch date under settlement	July 1, 2023
Merits decision	None reported

Boehringer developed BI 695501 as a biosimilar to Humira. AbbVie filed suit after receiving the statutory disclosures associated with Boehringer's biosimilar application. The litigation was part of AbbVie's broader effort to enforce the Humira patent estate against biosimilar developers.

The case was not a dispute over whether Boehringer had demonstrated biosimilarity. FDA approval addressed biosimilarity and manufacturing requirements. The litigation addressed patent infringement and the timing of commercial entry.

Which patents did AbbVie assert against Boehringer?

AbbVie asserted a group of Humira-related patents covering formulation technology, dosing, and therapeutic use. The public pleadings identified patents including the following:

U.S. patent	General subject matter
8,889,135	Adalimumab formulations and stabilizing components
9,090,689	Methods involving adalimumab treatment
9,296,184	Formulation and pharmaceutical composition claims
9,340,614	Adalimumab treatment methods
9,365,581	Formulation-related claims
9,403,871	Therapeutic use and dosing claims
9,464,040	Adalimumab formulation or treatment claims
9,512,216	Formulation-related claims

The asserted portfolio included both composition-of-matter-style formulation claims and method-of-use claims. The case therefore presented two different infringement theories:

1. Boehringer's biosimilar product allegedly practiced protected formulation technology.
2. The proposed labeling or commercial use allegedly encouraged infringement of patented adalimumab treatment methods.

The precise scope of asserted claims can differ from the full scope of a patent. Patent listing, claim construction, infringement contentions, and settlement terms determine the practical relevance of each patent. The docket did not produce a final claim-construction or infringement ruling in this case.

What was the Paragraph IV or BPCIA basis for the lawsuit?

Boehringer's biosimilar application triggered the BPCIA patent-exchange process. AbbVie then filed an infringement action under 35 U.S.C. § 271(e)(2), the statutory provision that permits a reference-product sponsor to sue based on the filing of an application seeking approval of a potentially infringing product.

Biosimilar litigation differs from conventional generic litigation under the Hatch-Waxman Act. A biosimilar applicant does not submit a Paragraph IV certification for an Orange Book-listed drug. The relevant process involves:

• Exchange of patent and application information under the BPCIA.
• Disclosure of the applicant's commercial-marketing intentions.
• Potential infringement litigation before launch.
• A negotiated launch date or separate statutory remedies.

Cyltezo was a biologic product, not a small-molecule generic. Its relevant patent records are associated with the FDA's Purple Book framework rather than an Orange Book listing for the active biologic. The case therefore should not be characterized as an Orange Book Paragraph IV action.

When did AbbVie and Boehringer settle?

AbbVie and Boehringer settled the U.S. adalimumab patent dispute in September 2018. AbbVie disclosed the settlement in its public filings, while the commercial and legal terms were not fully made public.[1]

The settlement ended the Delaware action without a judicial determination that the asserted patents were valid, infringed, or enforceable. The agreement effectively converted patent litigation risk into a negotiated market-entry date.

Settlement timeline

Date	Event
2016	Boehringer pursued FDA approval for BI 695501
2017	FDA approved Cyltezo as a biosimilar to Humira
2017	AbbVie filed the Delaware patent action
September 2018	AbbVie and Boehringer settled the U.S. dispute
October 2021	FDA designated Cyltezo interchangeable with Humira
July 1, 2023	Cyltezo became eligible for U.S. commercial launch under the settlement
2023 onward	Cyltezo entered the U.S. market amid broader Humira biosimilar competition

The settlement date did not provide immediate U.S. market access. Boehringer's launch was deferred until the contractually agreed date.

What was the effect of the settlement agreement?

The settlement gave Boehringer a defined pathway to commercialize Cyltezo in the United States before expiration of all asserted Humira patents. AbbVie avoided the uncertainty of trial, claim construction, validity challenges, and possible adverse rulings.

The public record does not disclose a complete financial license structure. The agreement is best understood as a patent settlement and entry license, rather than as a conventional research or technology-transfer licensing deal. It resolved the asserted U.S. claims and established the permitted entry date.

The settlement did not eliminate every potential patent issue involving adalimumab. It resolved the claims and parties covered by the agreement. Other AbbVie patents, later-issued patents, foreign patents, regulatory exclusivities, manufacturing rights, and separate litigation could have different legal effects.

What was the FDA status of Cyltezo?

The FDA approved Cyltezo, adalimumab-adbm, in October 2017 as a biosimilar to Humira.[2] The approval covered multiple inflammatory diseases for which Humira was approved, including rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, and hidradenitis suppurativa, subject to the approved labeling.

In October 2021, the FDA approved Cyltezo as interchangeable with Humira.[3] Interchangeability can support pharmacy-level substitution under state law, although the commercial impact depends on payer contracts, state substitution rules, channel strategy, and prescriber behavior.

Cyltezo's FDA approval and interchangeability designation were regulatory milestones. Neither determination invalidated AbbVie's patents or independently established freedom to operate. The 2018 settlement supplied the commercial authorization for U.S. entry.

What patents protected Humira outside this case?

Humira's patent protection was layered. The principal categories included:

Formulation patents

Formulation patents covered features such as:

• Concentration of adalimumab.
• Buffer systems.
• Surfactants.
• Stabilizers.
• pH ranges.
• Reduced immunogenicity or improved storage properties.
• Liquid formulations suitable for prefilled syringes or autoinjectors.

Formulation patents were commercially important because a biosimilar can have the same active antibody while using a formulation that creates separate infringement questions.

Method-of-use patents

AbbVie also held patents directed to the use of adalimumab for specific diseases, dosing regimens, and patient populations. These patents created potential inducement issues where a biosimilar label included indications covered by valid patent claims.

Skinny labeling can reduce method-of-use exposure in some circumstances. It does not automatically eliminate risk where the product, promotional activity, or remaining label supports an infringing use.

Device and presentation patents

Humira-related protection also could involve delivery devices, injector systems, containers, and presentation formats. Those rights can affect a biosimilar's commercial configuration even when the active pharmaceutical ingredient is not disputed.

Manufacturing and process rights

Biologics depend on cell-line development, upstream and downstream processing, purification, analytical characterization, and formulation operations. Process patents can create freedom-to-operate issues even after product patents expire. Manufacturing rights are often more difficult to evaluate publicly because confidential know-how, trade secrets, and contract manufacturing arrangements may be more important than published patent claims.

Did the case involve Orange Book patents?

No. Humira is a biologic, so the dispute did not operate through the small-molecule Orange Book patent-certification system.

The relevant regulatory framework was the BPCIA, and the relevant FDA reference-product records were associated with the Purple Book. The case still involved statutory patent litigation under Section 271(e)(2), but the procedural path was not a conventional Paragraph IV challenge to an Orange Book-listed drug.

What was the litigation status and outcome?

The litigation concluded through settlement rather than trial. There was no reported Delaware decision determining that Boehringer's Cyltezo infringed the asserted patents. There was also no reported judgment invalidating the patents.

Litigation issue	Outcome
Infringement liability	Not adjudicated
Patent validity	Not adjudicated
Claim construction	No final merits ruling
Injunction	No merits injunction reported
Settlement	Yes
Commercial entry	Permitted July 1, 2023
Public financial terms	Not fully disclosed

The absence of a merits opinion limits the case's value as precedent. Its main commercial significance is the negotiated entry date and the confirmation that AbbVie used settlement agreements to manage the timing of Humira biosimilar competition.

How strong was AbbVie's patent position?

AbbVie's position was commercially strong but legally untested in this action.

The estate's strengths included:

• Multiple patents directed to different technical features.
• Formulation claims that could apply to commercially viable adalimumab products.
• Method-of-use claims covering major Humira indications.
• A large portfolio that increased litigation cost and launch uncertainty.
• The ability to negotiate staggered biosimilar entry dates.

The principal weaknesses were typical of secondary patent estates:

• Later-issued formulation and method patents faced validity and claim-scope challenges.
• Patent expiration dates varied.
• Some claims could be designed around through alternative formulations or labeling.
• Biosimilar applicants could challenge patents through litigation or administrative proceedings.
• A settlement prevented AbbVie from obtaining a judicial validation of the asserted claims.

The case therefore supports a distinction between patent-count strength and enforceability strength. AbbVie had a dense portfolio, but the Delaware action did not establish the percentage of that portfolio that would have survived invalidity and infringement challenges.

How did the case affect Humira's revenue exposure?

Humira was AbbVie's largest product. AbbVie reported global Humira net revenues of approximately $21.2 billion in 2022, followed by a substantial decline after U.S. biosimilar launches began in 2023.[4]

Cyltezo was one of several U.S. adalimumab biosimilars entering under settlements with AbbVie. The agreement with Boehringer reduced the risk of an immediate launch by setting a date, but it did not prevent market erosion after July 2023.

Revenue exposure depended on:

• The number of biosimilars entering the market.
• Whether products were interchangeable.
• Formulary placement.
• Rebates and net pricing.
• Physician and pharmacy substitution.
• Medicare and commercial payer adoption.
• Patient assistance and channel strategy.

The commercial effect of the case was therefore timing-related. It delayed one competitor's U.S. entry while preserving AbbVie's ability to compete commercially before and after launch.

Which companies challenged Humira's patent estate?

AbbVie faced multiple biosimilar developers, including:

• Amgen, with Amjevita, adalimumab-atto.
• Samsung Bioepis, with Hadlima, adalimumab-bwwd.
• Boehringer Ingelheim, with Cyltezo, adalimumab-adbm.
• Sandoz, with Hyrimoz, adalimumab-adaz.
• Pfizer, with Abrilada, adalimumab-afzb.
• Organon and Celltrion, with Hadlima-related or Yuflyma-related products.
• Fresenius Kabi, with Idacio, adalimumab-aacf.

AbbVie resolved disputes with different developers through separate agreements. Entry dates and commercial rights varied by company and jurisdiction. The Boehringer settlement should not be treated as controlling the launch terms for other biosimilars.

What generic or biosimilar entry risks remained after settlement?

The case eliminated the immediate dispute between AbbVie and Boehringer but left several residual risks:

1. Other patent families could affect Cyltezo or competing adalimumab products.
2. Product-specific formulations could trigger separate infringement claims.
3. Method-of-use patents could create labeling and inducement exposure.
4. Device patents could affect autoinjector or prefilled-syringe presentations.
5. Manufacturing patents could affect process freedom to operate.
6. State substitution rules could limit the effect of interchangeability.
7. Payer contracting could produce faster-than-expected or slower-than-expected erosion.

For AbbVie, the principal risk was not a single adverse judgment. It was cumulative erosion from multiple biosimilars entering under separate settlements.

How did Boehringer's patent position compare with AbbVie's?

Boehringer was primarily a biosimilar applicant and commercial entrant in this dispute. Its strategic position depended on:

• FDA approval of Cyltezo.
• Scientific and manufacturing support for biosimilarity.
• A negotiated license or settlement from AbbVie.
• Interchangeability status.
• Commercial contracting and supply capacity.

AbbVie controlled the reference-product patent estate. Boehringer's leverage came from its ability to challenge patents, pursue FDA approval, develop a commercially viable biosimilar, and accept a negotiated launch date.

The settlement shifted the dispute from binary litigation risk to controlled market access. AbbVie retained time. Boehringer obtained certainty.

Key Takeaways

• The case involved Humira and Boehringer's adalimumab biosimilar, Cyltezo.
• AbbVie asserted a portfolio of formulation, treatment-method, and related Humira patents.
• The lawsuit proceeded under the BPCIA, not the Orange Book Paragraph IV process.
• The parties settled in September 2018.
• Cyltezo's U.S. launch was permitted on July 1, 2023.
• No final court decision determined infringement, validity, or enforceability.
• FDA approval and interchangeability did not independently resolve patent rights.
• The settlement protected AbbVie from immediate entry but did not prevent later U.S. biosimilar erosion.
• The case has limited precedential value because it ended without a merits ruling.

FAQs About AbbVie v. Boehringer Ingelheim

Did Boehringer win the AbbVie Humira patent lawsuit?

Neither party obtained a merits judgment. The case ended through settlement, with Boehringer receiving a negotiated U.S. launch date.

Was Cyltezo interchangeable with Humira?

Yes. The FDA designated Cyltezo interchangeable with Humira in October 2021.[3]

Did AbbVie license Humira patents to Boehringer?

The settlement resolved the patent dispute and permitted commercial entry, but the complete licensing and financial terms were confidential.

Did the lawsuit delay Cyltezo's FDA approval?

No. FDA approved Cyltezo in 2017. The settlement controlled the timing of U.S. commercial launch, not the FDA's scientific approval decision.

Could AbbVie sue Boehringer again after the settlement?

The settlement likely defined the released claims and permitted activities, but later disputes could depend on the agreement's scope, newly issued patents, product changes, or conduct outside the settlement. The Delaware case itself did not produce a public merits ruling.

References

1. AbbVie Inc. (2018). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2018. U.S. Securities and Exchange Commission.

2. U.S. Food and Drug Administration. (2017, October 31). FDA approves Cyltezo, a biosimilar to Humira. https://www.fda.gov

3. U.S. Food and Drug Administration. (2021, October 15). FDA approves Cyltezo as interchangeable biosimilar to Humira. https://www.fda.gov

4. AbbVie Inc. (2023). Annual report pursuant to Section 13 or 15(d) of the Securities Exchange Act of 1934 for the fiscal year ended December 31, 2022. U.S. Securities and Exchange Commission.

5. U.S. District Court for the District of Delaware. (2017). AbbVie Inc. v. Boehringer Ingelheim International GmbH, No. 1:17-cv-01065. Civil docket and pleadings.